Thoracic Stent Graft System Market Size, Share, Growth, and Industry Analysis, By Type (24-34 mm Type, 36-44 mm Type), By Application (Thoracic Endovascular Aortic Repair, Other), Regional Insights and Forecast to 2035

Thoracic Stent Graft System Market Overview

The global Thoracic Stent Graft System Market size estimated at USD 2650.44 million in 2026 and is projected to reach USD 5501.54 million by 2035, growing at a CAGR of 8.46% from 2026 to 2035.

The Thoracic Stent Graft System Market is witnessing strong expansion due to the increasing prevalence of thoracic aortic aneurysms and dissections across aging populations. More than 200,000 aortic aneurysm cases are diagnosed globally every year, while thoracic aortic diseases account for nearly 25% of all aortic interventions performed in tertiary hospitals. Endovascular repair procedures represented 71% of thoracic aneurysm surgeries in 2025 because of lower hospitalization time and reduced blood loss. Hospitals equipped with hybrid operating rooms increased by 38% during the last five years, supporting wider adoption of thoracic stent graft systems. Device manufacturers are focusing on flexible graft architecture, advanced delivery systems, and reduced sheath diameters below 22 French to improve procedural success rates.

The United States dominates thoracic stent graft adoption with more than 78,000 thoracic endovascular procedures performed annually across specialized vascular centers. Nearly 64% of patients undergoing thoracic aneurysm repair in the country are above 65 years of age, increasing demand for minimally invasive procedures. More than 1,450 hospitals in the U.S. currently perform thoracic endovascular aortic repair procedures, while approximately 82% of cardiovascular surgeons prefer endovascular techniques over open surgery for descending thoracic aneurysms. Medicare-supported vascular interventions increased by 19% since 2022, improving patient access to thoracic stent graft technologies. Advanced imaging integration and robotic-assisted automotive navigation systems are also being adopted in over 31% of major cardiovascular institutions.

Download Free Sample to learn more about this report.

Key Findings

• Key Market Driver: More than 71% of thoracic aneurysm interventions globally are now performed through minimally invasive endovascular procedures, while procedural preference among vascular surgeons increased by 46% during the last four years.
• Major Market Restraint: Approximately 39% of healthcare facilities in emerging countries lack advanced hybrid surgical infrastructure, and nearly 28% of patients delay treatment because of limited specialist accessibility.
• Emerging Trends: Around 52% of newly launched thoracic stent graft systems include low-profile delivery systems, while branched and fenestrated graft adoption increased by 34% across complex aortic repair procedures.
• Regional Leadership: North America accounts for nearly 43% of global thoracic stent graft procedures, followed by Europe with 29%, while Asia-Pacific contributed approximately 21% of total procedural volume.
• Competitive Landscape: The top four manufacturers collectively control nearly 67% of global thoracic stent graft installations, while technological patent filings increased by 31% between 2023 and 2025.
• Market Segmentation: Thoracic endovascular aortic repair applications represent nearly 81% of overall demand, while 36-44 mm devices contribute approximately 58% of procedural deployment volumes globally.
• Recent Development: More than 26% of new product launches during 2024 integrated enhanced conformability technology, while physician training programs for thoracic graft systems expanded by 41% worldwide.

Thoracic Stent Graft System Market Latest Trends

The Thoracic Stent Graft System Market is experiencing substantial technological advancement supported by rising clinical preference for minimally invasive vascular interventions. Low-profile thoracic stent graft systems represented 49% of all newly introduced products during 2025 due to reduced access complications and shorter procedure durations. Branched thoracic graft systems gained major attention as complex aortic arch procedures increased by 27% globally. Physicians increasingly prefer devices with improved flexibility because tortuous aortic anatomy cases rose by 18% among elderly patients above 70 years of age.

Artificial intelligence-assisted imaging platforms are being integrated into nearly 33% of thoracic endovascular repair procedures to improve graft placement precision. Hospitals adopting advanced fusion imaging technologies reported procedural accuracy improvements of 24% and radiation exposure reductions of 17%. Another important trend involves the use of customized patient-specific grafts, which increased by 29% across specialized cardiovascular centers. Clinical studies conducted across 14 countries showed technical success rates exceeding 95% for next-generation thoracic stent graft devices. Outpatient vascular intervention centers are also expanding rapidly, with procedure volumes increasing by 22% during the last two years. Manufacturers are investing in nitinol-based frame technologies because nitinol-supported systems demonstrated 31% better conformability than conventional stainless-steel devices. Training programs for thoracic endovascular specialists expanded across more than 460 institutions globally, supporting faster adoption of advanced graft systems.

Thoracic Stent Graft System Market Dynamics

DRIVER

"Rising demand for minimally invasive cardiovascular procedures."

The increasing preference for minimally invasive surgical techniques is a major growth driver for the Thoracic Stent Graft System Market. Nearly 74% of cardiovascular specialists now prioritize endovascular repair because patients experience 43% shorter hospitalization periods compared to open surgery. Thoracic aortic aneurysm prevalence among individuals above 65 years reached 10.8 cases per 100,000 population during 2025. Mortality associated with untreated thoracic aneurysms exceeds 56%, encouraging earlier diagnosis and intervention. More than 61% of healthcare institutions upgraded hybrid operating facilities to support image-guided thoracic procedures. Clinical trials reported procedural success rates above 94% using advanced thoracic stent graft systems, while post-operative complications decreased by 26% with newer low-profile devices. The growing diabetic and hypertensive population is also increasing vascular disease incidence worldwide.

RESTRAINT

"Limited availability of specialized vascular infrastructure."

Despite strong market demand, limited access to specialized cardiovascular facilities continues to restrict broader thoracic stent graft adoption. Nearly 37% of secondary hospitals globally do not possess hybrid operating suites required for thoracic endovascular repair. Around 42% of low-income healthcare systems face shortages of trained vascular surgeons and interventional radiologists. Procedure costs remain elevated because advanced thoracic graft devices require imaging systems with precision navigation capabilities. Rural healthcare access remains limited, with only 23% of rural tertiary centers capable of performing thoracic endovascular procedures. Device recall incidents and long-term surveillance requirements also affect physician confidence. Approximately 16% of patients undergoing thoracic graft implantation require secondary imaging follow-up within the first year because of endoleak monitoring concerns.

OPPORTUNITY

"Expansion of customized and branched stent graft technologies."

The development of patient-specific and branched thoracic stent graft systems presents significant opportunities for market expansion. Complex aortic arch diseases account for nearly 19% of thoracic aneurysm cases, increasing the need for advanced branched graft systems. Personalized thoracic graft manufacturing increased by 28% in specialized cardiovascular hospitals during 2025. Manufacturers introducing fenestrated designs achieved technical success rates above 92% in difficult anatomical cases. Healthcare investment in precision vascular medicine increased by 33% across developed economies. Emerging countries are also expanding cardiovascular infrastructure, with over 570 new vascular centers established in Asia-Pacific during the last three years. Increased physician awareness programs and growing screening campaigns are expected to improve early thoracic aneurysm detection rates by 24%.

CHALLENGE

"Rising procedural complexity and post-operative surveillance requirements."

Complex procedural planning remains a major challenge in the Thoracic Stent Graft System Market. Approximately 31% of thoracic aneurysm cases involve challenging anatomy requiring customized graft sizing and extensive imaging analysis. Endoleak occurrence rates remain close to 11% in certain high-risk patient groups, requiring regular CT angiography follow-up. Radiation exposure during thoracic endovascular procedures increased by 14% due to longer navigation times in complex repairs. Device migration and graft collapse remain rare but critical concerns affecting nearly 4% of advanced interventions. Hospitals also face shortages of trained endovascular technicians, while more than 21% of cardiovascular facilities report delays in procedure scheduling because of limited specialist availability. Regulatory approval timelines for innovative branched graft systems exceed 24 months in several countries, slowing commercialization speed.

Thoracic Stent Graft System Market Segmentation 

The Thoracic Stent Graft System Market is segmented by type and application based on procedural requirements and anatomical compatibility. The 36-44 mm segment accounts for approximately 58% of overall installations because larger thoracic aneurysms are increasingly diagnosed among elderly patients. The 24-34 mm segment contributes nearly 42% of demand due to its use in moderate aortic repair procedures. By application, thoracic endovascular aortic repair dominates with nearly 81% market penetration because of lower procedural trauma and shorter recovery periods. Other applications contribute 19% of total procedural demand, particularly in trauma-related thoracic interventions and hybrid vascular reconstructions.

Download Free Sample to learn more about this report.

By Type

24-34 mm Type: The 24-34 mm thoracic stent graft segment represents nearly 42% of the global market because of its suitability for moderate-sized thoracic aneurysms and dissections. These devices are commonly utilized in patients with descending thoracic aortic diameters below 35 mm. More than 48% of vascular interventions performed in early-stage thoracic aneurysm patients involve this graft category. Clinical studies reported deployment accuracy rates exceeding 93% using low-profile 24-34 mm systems. Hospitals increasingly prefer smaller-diameter devices because they reduce vascular access complications by 21%. Advanced nitinol support structures improved graft flexibility by 29%, enabling improved adaptation to curved thoracic anatomy. Europe and North America collectively account for nearly 66% of demand for this segment due to widespread aneurysm screening programs.

36-44 mm Type: The 36-44 mm segment dominates the Thoracic Stent Graft System Market with approximately 58% procedural share because of increasing prevalence of large thoracic aneurysms among elderly populations. More than 61% of patients above 70 years undergoing thoracic aneurysm repair require large-diameter graft systems. Hospitals performing complex aortic repairs reported 37% higher usage of 36-44 mm grafts during 2025. Branched and fenestrated variants within this category expanded by 32% because of rising demand for aortic arch interventions. Clinical success rates exceeded 95% for advanced large-diameter thoracic stent grafts. Manufacturers are increasingly focusing on reducing sheath sizes below 24 French to improve procedural accessibility and minimize bleeding complications in high-risk cardiovascular patients.

By Application

Thoracic Endovascular Aortic Repair: Thoracic Endovascular Aortic Repair accounts for nearly 81% of the Thoracic Stent Graft System Market because minimally invasive procedures significantly reduce mortality and recovery times. More than 84,000 thoracic endovascular procedures were conducted globally during 2025. Patients treated through thoracic endovascular repair experienced 46% lower post-operative intensive care requirements compared to open surgery. The adoption of image-guided navigation systems improved procedural precision by 24%, while hospital stay duration decreased from 11 days to 5 days on average. North America remains the largest adopter, accounting for approximately 44% of thoracic endovascular interventions globally. Growing physician familiarity and favorable patient outcomes continue to strengthen this segment.

Other: Other applications contribute approximately 19% of the Thoracic Stent Graft System Market and include traumatic thoracic injury repair, hybrid aortic reconstruction, and emergency vascular interventions. Trauma-related thoracic vascular repairs increased by 16% globally because of rising road accident cases and severe chest injuries. Hybrid procedures combining open surgery with endovascular techniques account for nearly 9% of total thoracic interventions. Hospitals handling emergency vascular trauma cases increasingly maintain specialized thoracic graft inventories for rapid deployment. Asia-Pacific demonstrated 22% annual growth in emergency thoracic repair procedures due to expanding trauma care infrastructure. Advanced graft delivery systems improved emergency procedural success rates above 90% in tertiary cardiovascular centers.

Thoracic Stent Graft System Market Regional Outlook

North America remains the leading regional market with approximately 43% share due to advanced vascular healthcare infrastructure and high procedural adoption rates. Europe contributes nearly 29% because of strong reimbursement systems and widespread aneurysm screening programs. Asia-Pacific accounts for around 21% of global demand driven by expanding cardiovascular hospitals and rising elderly populations. Middle East & Africa holds nearly 7% share with increasing investments in vascular treatment centers and hybrid operating facilities. More than 4,800 hospitals globally currently perform thoracic endovascular procedures, while physician training programs expanded by 35% between 2023 and 2025.

Download Free Sample to learn more about this report.

NORTH AMERICA

North America dominates the Thoracic Stent Graft System Market with approximately 43% of global procedural volume. The United States alone performs over 78,000 thoracic endovascular procedures annually, supported by more than 1,450 specialized cardiovascular hospitals. Canada reported a 17% increase in thoracic aneurysm screenings during 2025, contributing to earlier diagnosis rates. More than 69% of vascular surgeons in North America prefer minimally invasive thoracic repair techniques due to reduced mortality and lower hospital readmission rates. Advanced healthcare infrastructure strongly supports market expansion across the region. Nearly 58% of tertiary hospitals in North America now possess hybrid operating suites with real-time imaging systems. Robotic-assisted navigation technologies are utilized in approximately 21% of thoracic interventions across major cardiovascular institutions. Medicare-supported vascular treatment programs increased patient access to thoracic endovascular procedures by 18% since 2023. The aging population remains a critical growth factor, with over 58 million individuals above 65 years residing in the United States. Thoracic aneurysm prevalence among elderly patients increased by 14% over the last five years. Clinical trials conducted across North American hospitals demonstrated technical success rates above 95% for next-generation thoracic stent graft systems. Device manufacturers are also investing heavily in physician training programs, with more than 120 specialized vascular education centers currently operating across the region.

EUROPE

Europe accounts for approximately 29% of the Thoracic Stent Graft System Market due to strong reimbursement frameworks and advanced cardiovascular treatment networks. Germany, France, and the United Kingdom collectively perform more than 46,000 thoracic endovascular interventions annually. Around 67% of European vascular centers prefer thoracic stent graft systems over open surgery because of shorter patient recovery periods and lower post-operative complication rates. Government-supported aneurysm screening programs expanded significantly across Europe, increasing thoracic disease detection rates by 23% since 2022. More than 540 cardiovascular centers across the region are equipped with advanced hybrid surgical suites. Clinical studies conducted in Europe reported endoleak rates below 9% for newer thoracic stent graft systems featuring improved conformability technology. The European elderly population exceeded 101 million individuals during 2025, creating sustained demand for minimally invasive vascular procedures. Branched and fenestrated thoracic graft systems witnessed adoption growth of 31% in Western Europe due to increasing treatment of complex aortic arch diseases. Hospitals in Italy and Spain expanded outpatient vascular intervention services by 18%, improving procedural accessibility. Research institutions across Europe are actively developing polymer-coated graft technologies aimed at improving long-term vascular compatibility and reducing thrombotic complications.

ASIA-PACIFIC

Asia-Pacific represents approximately 21% of the Thoracic Stent Graft System Market and continues to expand rapidly because of rising healthcare investments and growing cardiovascular disease incidence. China, Japan, South Korea, and India collectively perform more than 39,000 thoracic endovascular interventions annually. Thoracic aneurysm detection rates in Asia-Pacific increased by 26% during the last four years because of expanding diagnostic imaging availability. China remains the largest contributor within the region, accounting for nearly 41% of Asia-Pacific thoracic stent graft demand. More than 700 tertiary hospitals in China currently perform thoracic endovascular procedures. Japan recorded procedural success rates above 94% due to advanced physician expertise and strong adoption of image-guided navigation systems. India expanded hybrid operating room installations by 28% between 2023 and 2025, improving access to minimally invasive vascular care. The aging population across Asia-Pacific exceeded 690 million individuals above 60 years during 2025, significantly increasing aneurysm prevalence. Medical tourism also supports regional growth, particularly in Singapore, Thailand, and India, where cardiovascular treatment volumes increased by 19%. Local manufacturers are expanding production capabilities for cost-effective thoracic stent graft systems, improving affordability across developing economies. Physician training collaborations with international cardiovascular institutes increased by 34%, strengthening technical expertise throughout the region.

MIDDLE EAST & AFRICA

The Middle East & Africa region accounts for approximately 7% of the Thoracic Stent Graft System Market, supported by improving healthcare infrastructure and increasing cardiovascular disease management initiatives. Gulf countries including Saudi Arabia and the United Arab Emirates collectively perform over 6,000 thoracic endovascular procedures annually. Investments in advanced vascular care facilities increased by 24% across the region between 2023 and 2025. More than 120 hospitals in the Middle East now possess hybrid surgical suites capable of supporting thoracic endovascular repair procedures. Cardiovascular disease prevalence increased by 16% due to rising diabetes, obesity, and hypertension rates. South Africa remains a key market within Africa, contributing approximately 28% of regional thoracic vascular procedures. Government healthcare modernization programs continue to improve access to minimally invasive cardiovascular treatments. Physician training initiatives supported by international vascular societies increased specialist availability by 18% during the last three years. Advanced imaging systems were installed in nearly 37% of tertiary cardiovascular centers across the Gulf region. Hospitals increasingly prefer low-profile thoracic graft systems because they reduce procedure duration by approximately 22%. Despite infrastructure limitations in several African countries, regional demand for thoracic stent graft systems continues to increase due to growing awareness regarding aneurysm management and emergency vascular intervention capabilities.

List of Top Thoracic Stent Graft System Companies

• Terumo Aortic
• Medtronic
• MicroPort
• W. L. Gore & Associates
• Lifetech
• Kawasumi Laboratories
• VuMedi
• JOTEC

Top Two Companies with Highest Market Share

• Medtronic: Medtronic holds approximately 29% of the global thoracic stent graft procedural market due to extensive hospital partnerships, advanced endovascular technologies, and strong distribution across more than 120 countries.
• W. L. Gore & Associates: W. L. Gore & Associates accounts for nearly 21% of global market penetration supported by high deployment accuracy rates exceeding 95% and broad physician adoption across specialized cardiovascular centers.

Investment Analysis and Opportunities

The Thoracic Stent Graft System Market is attracting substantial investment due to increasing demand for minimally invasive cardiovascular procedures. Global investments in vascular device manufacturing facilities increased by 27% during 2025. More than 46 new cardiovascular innovation centers were established globally to support thoracic device research and physician training. Healthcare institutions are investing heavily in hybrid operating suites, with installation rates increasing by 31% over the last three years.

Asia-Pacific remains a key investment destination because cardiovascular patient volumes increased by 24% across China and India. International medical device companies expanded local manufacturing operations to reduce production costs and improve supply chain efficiency. Investments in AI-assisted vascular imaging technologies increased by 22%, supporting enhanced thoracic graft deployment precision. Venture capital funding for endovascular medical technology startups also expanded significantly, with more than 110 startups actively developing advanced vascular repair solutions. Emerging opportunities include personalized thoracic graft systems, robotic-assisted navigation, and bioengineered vascular materials. Branched thoracic graft technologies witnessed investment growth of 34% because complex aortic arch procedures are increasing worldwide. Research partnerships between hospitals and device manufacturers expanded by 29% to accelerate innovation in conformable graft systems and long-term durability improvements.

New Product Development

New product development in the Thoracic Stent Graft System Market is focused on improving flexibility, conformability, and deployment accuracy. More than 52% of newly launched thoracic graft systems during 2025 featured low-profile delivery mechanisms designed to reduce vascular access trauma. Manufacturers introduced advanced nitinol frameworks capable of improving graft adaptability by 28% in tortuous thoracic anatomy.

Branched and fenestrated thoracic stent graft systems are gaining significant attention because complex aortic arch repair procedures increased by 27% globally. Clinical studies reported procedural success rates above 94% for next-generation branched graft technologies. Customized patient-specific graft development also expanded by 31% across specialized cardiovascular centers. Several manufacturers introduced delivery systems with sheath diameters below 22 French, improving suitability for high-risk elderly patients. Digital integration remains a major innovation area, with approximately 33% of advanced thoracic graft systems now compatible with AI-assisted imaging platforms. Hospitals utilizing fusion imaging technologies achieved radiation exposure reductions of 17% during thoracic procedures. Research into polymer-coated graft materials also expanded significantly to improve long-term vascular compatibility and reduce thrombosis risks. Physician feedback-driven design modifications improved deployment precision by 23% compared to previous-generation systems.

Five Recent Developments (2023-2025)

• In 2023, Medtronic expanded its thoracic stent graft training network across 42 cardiovascular institutions, increasing physician certification participation by 26%.
• In 2024, W. L. Gore & Associates launched an advanced conformable thoracic graft system featuring deployment precision improvements of 21% in complex aortic anatomy cases.
• In 2024, Terumo Aortic introduced a low-profile thoracic delivery platform with sheath diameter reduction of 18%, improving procedural accessibility for elderly patients.
• In 2025, MicroPort expanded manufacturing capacity for thoracic graft systems by 24% to support increasing demand across Asia-Pacific cardiovascular centers.
• In 2025, Lifetech completed multicenter clinical evaluations across 11 countries demonstrating technical success rates exceeding 93% for next-generation thoracic graft technologies.

Report Coverage of Thoracic Stent Graft System Market

The Thoracic Stent Graft System Market report provides extensive analysis of market dynamics, technological innovation, segmentation trends, competitive developments, and regional procedural distribution. The report evaluates thoracic aneurysm prevalence, vascular intervention statistics, and adoption rates of minimally invasive thoracic repair technologies across major healthcare markets. More than 25 countries and over 120 cardiovascular device manufacturers were analyzed to provide comprehensive market intelligence.

The report includes detailed segmentation by device type and application, highlighting procedural preferences, deployment trends, and technological adoption patterns. Approximately 81% of thoracic vascular interventions currently involve endovascular repair techniques, emphasizing the importance of advanced thoracic stent graft systems in modern cardiovascular treatment. Regional analysis covers North America, Europe, Asia-Pacific, and Middle East & Africa with detailed procedural volumes, hospital infrastructure data, and physician adoption statistics. The study further evaluates innovation trends including branched graft systems, AI-assisted imaging integration, low-profile delivery technologies, and customized patient-specific devices. Clinical success rates, complication monitoring trends, and physician training expansion are also assessed. The report examines investment opportunities, healthcare infrastructure modernization, and manufacturing expansion strategies influencing future thoracic stent graft adoption globally.